• Antibody-drug conjugates
• Targeting platform – 'OptiLink'
• Light activated cancer therapy – 'ProstaLite'
• MRI contrast agents & imaging
• Photosensitiser innovations
• Additional products and applications

• Investment History & Strategy
• Partnering opportunities

• Press Releases
• News Items
• Scientific Publications

• Background
• Achievements
• The Team
• Sitemap

Investment History & Strategy

• 2010 - Funds from a syndicate of new investors from the LBA (London Business Angels).
• 2009 - Funds from the existing investors
• 2007 - Matching funding to EU grant from existing and a new investor
• 2006 - Significant grant funding (€300,000) through the European Union Framework VI initiative
• 2006 - Bridge financing
• 2005 - Significant funding (despite the savage downturn in life-sciences private equity investment) from private equity funds advised by Clubb Biocapital
• 2001 - Seed financing from Imperial College University Challenge Seed Fund and three experienced business angels.

PhotoBiotics is now ready to approach prospective development and commercialisation partners for its lead product, ProstaLite, for treatment of prostate cancer.

PhotoBiotics also intends to validate other cancer targets, which will enhance the value of the OptiLink platform. The Directors believe that the OptiLink platform will be extremely attractive to companies with complementary technologies, in particular to companies already in the PDT or imaging space and also to antibody companies, as well as to big pharma companies seeking to target their small molecule drugs.

These opportunities and PhotoBiotics’ semi-virtual business model, its research collaborations and ability to leverage the expertise and facilities at Imperial College, make it a lean, flexible and efficient organisation – and an exciting merger or trade sale opportunity, which will provide an attractive exit for investors.

If you are interested in the investment opportunities described here, please contact us to discuss your interest.